Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
NCT07132112Phase 1Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Oct 2025
- Primary completion
- Aug 2028
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT719 in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM) and systemic sclerosis (SSc), sponsored by Grit Biotechnology. Primary endpoints: Proportion of participants experiencing dose limiting toxicity at 28 days and Incidence of treatment-emergent adverse events at 2 years. Started Oct 2025; status: recruiting.
02
Drugs
GT719
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07132112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132112.